Within your organisation how many intra-vitreal vials/implants have been used in the latest 4 months, if possible between September and December 2015?
Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use.
Avastin (bevacizumab) Injections
Eylea (aflibercept) Injections
Illuvien (Fluocinolone) Impants
Lucentis (ranibizumab) Injections
Ozurdex (Dexamethasone) Implants
(Total Vials/Implants and Vials/Implants for Wet Age Related Macular Degeneration (wAMD)
Please find below the number of intra-vitreal injections/implants supplied to patients under the care of Ophthalmology at the Royal Surrey County Hospital NHS Foundation Trust between September and December 2015 (i.e. 1st September 2015 to 31st December 2015).
The Trust does not record the indication for treatment on the pharmacy dispensing system so the data may, therefore, include patients who have been treated with these drugs for indications other than those listed in the request
AFLIBERCEPT 40 mg per ml Injection 544
BEVACIZUMAB 1.25 mg in 0.05ml Intravitreal Injection 35
DEXAMETHASONE 0.7 mg Intravitreal Implant 31
FLUOCINOLONE ACETONIDE 190 micrograms Intravitreal Implant 3
RANIBIZUMAB 0.5 mg Injection 369